Papers - KIYOI, Hitoshi
-
A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Reviewed
Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H.
Cancer Immunol Res. Vol. 4 ( 8 ) page： 658-68 2016.8
-
SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Reviewed
Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H.
Cancer Sci. page： [Epub ahead of print] 2016.6
-
PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation. Reviewed
Inagaki Y, Hayakawa F, Hirano D, Kojima Y, Morishita T, Yasuda T, Naoe T, Kiyoi H.
Biochem Biophys Res Commun. Vol. 475 ( 2 ) page： 176-81 2016.6
-
Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Reviewed
Suzuki Y, Tomita A, Nakamura F, Iriyama C, Shirahata-Adachi M, Shimada K, Akashi A, Ishikawa Y, Kaneda N, Kiyoi H.
Cancer Sci. page： [Epub ahead of print] 2016.6
-
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Reviewed
Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H.
Oncotarget. page： [Epub ahead of print] 2016.6
-
Live-cell single-molecule imaging of the cytokine receptor MPL for analysis of dynamic dimerization. Reviewed
Sakamoto A, Tsukamoto T, Furutani Y, Sudo Y, Shimada K, Tomita A, Kiyoi H, Kato T, Funatsu T.
J Mol Cell Biol. page： [Epub ahead of print] 2016.6
-
BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. Reviewed
Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.
Cell Mol Immunol page： [Epub ahead of print] 2016.5
-
Identification of Meflin as a Potential Marker for Mesenchymal Stromal Cells. Reviewed
Maeda K, Enomoto A, Hara A, Asai N, Kobayashi T, Horinouchi A, Maruyama S, Ishikawa Y, Nishiyama T, Kiyoi H, Kato T, Ando K, Weng L, Mii S, Asai M, Mizutani Y, Watanabe O, Hirooka Y, Goto H, Takahashi M.
Sci Rep. Vol. 6 page： 22288 2016.2
-
B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia. Reviewed
Imoto N, Hayakawa F, Kurahashi S, Morishita T, Kojima Y, Yasuda T, Sugimoto K, Tsuzuki S, Naoe T, Kiyoi H.
J Biol Chem. Vol. 291 ( 9 ) page： 4723-31 2016.2
-
The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Reviewed
Kishimoto M, Suzuki N, Murata M, Ogawa M, Kanematsu T, Takagi A, Kiyoi H, Kojima T, Matsushita T.
Ann Hematol. Vol. 95 ( 3 ) page： 541-2 2016.2
-
A case of MYH9 disorders caused by a novel mutation (p.K74E). Reviewed
Kanematsu T, Suzuki N, Yoshida T, Kishimoto M, Aoki T, Ogawa M, Kagami Y, Kiyoi H, Matsushita T, Kunishima S.
Ann Hematol Vol. 95 ( 1 ) page： 161-3 2016.1
-
Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Reviewed
Kitamura K, Nishiyama T, Ishiyama K, Miyawaki S, Miyazaki K, Suzuki K, Masaie H, Okada M, Ogawa H, Imai K, Kiyoi H, Naoe T, Yokoyama Y, Chiba S, Hata T, Miyazaki Y, Hatta Y, Takeuchi J, Nannya Y, Kurokawa M, Ueda Y, Koga D, Sugiyama H, Takaku F.
Int J Hematol. Vol. 103 ( 1 ) page： 53-62 2016.1
-
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Reviewed
Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, Takizawa J, Mitani K, Igarashi T, Sakai K, Miyazaki K, Mihara K, Ohmachi K, Nakamura N, Takasaki H, Kiyoi H, Nakamura S, Kinoshita T, Ogura M.
Blood Cancer J. Vol. 5 page： e372 2015.12
-
Overview: A New Era of Cancer Genome in Myeloid Malignancies. Invited Reviewed
Kiyoi H.
Oncology. Vol. 89 ( Suppl 1 ) page： 1-3 2015.11
-
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Reviewed
Kobayashi Y, Yamauchi T, Kiyoi H, Sakura T, Hata T, Ando K, Watabe A, Harada A, Taube T, Miyazaki Y, Naoe T.
Cancer Sci. Vol. 106 ( 11 ) page： 1590-5 2015.11
-
Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. Reviewed
Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M.
J Immunol. Vol. 194 page： 911-20 2015
-
Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Reviewed
Sugimoto K, Hayakawa F, Shimada S, Morishita T, Shimada K, Katakai T, Tomita A, Kiyoi H, Naoe T.
Sci Rep. Vol. 5 page： 13054 2015
-
Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection. Reviewed
Hanajiri R, Murata M, Sugimoto K, Murase M, Sakemura R, Goto T, Watanabe K, Imahashi N, Terakura S, Ohashi H, Akatsuka Y, Kurahashi S, Miyamura K, Kiyoi H, Nishida T, Naoe T.
Bone Marrow Transplant Vol. 50 page： 1187-94 2015
-
FLT3 Inhibitors: Recent Advances And Problems For Clinical Application. Invited Reviewed
Kiyoi H
Nagoya J Med Sci Vol. 77 page： 7-17 2015
-
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. Reviewed
Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, Nishida T, Kiyoi H, Watamoto K, Kohno A, Kasai M, Kato C, Iida H, Naoe T, Miyamura K, Murata M; for the Nagoya Blood and Marrow Transplantation Group.
Ann Hematol Vol. 94 page： 1139-48 2015